- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Prenetics Global Ltd - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| Fr | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 15.07. | Prenetics Raises $1 Billion For IM8 Via General Catalyst's Customer Value Fund | 3 | pulse2.com | ||
| 14.07. | Prenetics Global Limited: Prenetics' IM8 Secures $1 Billion Growth Financing from General Catalyst's Customer Value Fund (CVF) | 4 | GlobeNewswire (USA) | ||
| PRENETICS GLOBAL Aktie jetzt für 0€ handeln | |||||
| 14.07. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 25.06. | Prenetics Global Limited (PRE) Receives Bullish Coverage as IM8 Targets Supplement Market Growth | 1 | Insider Monkey | ||
| 10.06. | Prenetics posts revenue growth, lifts 2026 outlook | 1 | Seeking Alpha | ||
| 10.06. | Prenetics raises 2026 IM8 revenue guidance on strong growth | 4 | Investing.com | ||
| 10.06. | Prenetics Global Limited: Prenetics Announces Record Q1 2026 Results with IM8 Revenue Reaching a Record ~$16.7 Million in May, Implying ~$200 Million in Annualized Recurring Revenue | 971 | GlobeNewswire (Europe) | Q1 2026 revenue of $36.0 million with IM8 revenue of $33.8 million, up 23.1% from IM8 revenue of $27.4 million in Q4 2025 and nearly 6x year-over-year from IM8 revenue of $5.7 million in Q1 2025Raises... ► Artikel lesen | |
| 04.06. | Prenetics Global Limited: Prenetics Appoints Hudson Leogrande, Founder and CEO of Multi-Billion-Dollar DTC Brand Comfrt, to Board of Directors as IM8 Accelerates TikTok and Meta Expansion | 10 | GlobeNewswire (USA) | ||
| 04.06. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.05. | Prenetics Global Limited: Prenetics Announces Jay Shetty as IM8 Global Ambassador and Shareholder in Multi-Year Partnership | 6 | GlobeNewswire (USA) | ||
| 14.05. | Prenetics Global Reports Q1 2026 Results: Full Earnings Call Transcript | 4 | Benzinga.com | ||
| 14.05. | Prenetics raises 2026 guidance on IM8 supplement growth | 2 | Investing.com | ||
| 14.05. | Prenetics Global Limited: Prenetics Welcomes Brian J. Rosin as Chief Financial Officer of IM8 | 479 | GlobeNewswire (Europe) | ~ Two-decade veteran of premium consumer health, nutrition, and direct-to-consumer brands joins IM8 to support its rapid global expansion NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global... ► Artikel lesen | |
| 14.05. | Prenetics Global reports Q1 results; gives Q2 and raises FY26 outlook | 3 | Seeking Alpha | ||
| 14.05. | Prenetics Global Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 07.05. | Prenetics Global Limited: Prenetics' IM8 Named Exclusive Health Supplements Partner of Inter Miami CF in Multi-Year Partnership | 2 | GlobeNewswire (USA) | ||
| 04.05. | Prenetics Global Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.04. | Prenetics Global Limited: Prenetics' IM8 Health Partners with Vitamin Angels to Combat Global Malnutrition, Commits to Impacting 400,000 Mothers and Children in Year One | 5 | GlobeNewswire (USA) |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS | 681,90 | +0,53 % | Megatrend Folger: Regeneron zündet den Kursturbo | Regeneron hat mit seinen jüngsten Quartalszahlen die Erwartungen deutlich übertroffen. Dupixent, Eylea in der höheren Dosierung und Libtayo wachsen kräftig, während die Aktie ihre monatelange Schwächephase... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,950 | +1,01 % | Viking Therapeutics, BioNxt Solutions, Bausch Health - Studienerfolg entfacht neue Fantasie | Die Pharmaindustrie steht vor einer neuen Wachstumsphase. Milliarden fließen in innovative Therapien, moderne Arzneimitteltechnologien und die Weiterentwicklung etablierter Medikamente. Besonders dynamisch... ► Artikel lesen | |
| CANSINO BIOLOGICS | 2,700 | +0,75 % | CanSino Biologics Inc: CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Further Expanding International Presence in South America | HONG KONG, June 29, 2026 - (ACN Newswire) - On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company's ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197)... ► Artikel lesen | |
| GUARDANT HEALTH | 146,64 | +0,58 % | Stifel raises Guardant Health stock price target on strong Q2 results | ||
| SINO BIOPHARM | 0,555 | -1,21 % | SBP GROUP Bemarituzumab Combined With Anlotinib Approved for New Indication | ||
| BIO-TECHNE | 62,50 | 0,00 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher ausgegebener Aktien an und alleiniger Kontrolle über Bio-Techne Corporation, Minneapolis, MN/USA | Datum der Anmeldung:23.07.2026Aktenzeichen:B3-84/26Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher ausgegebener Aktien an und alleiniger Kontrolle über Bio-Techne Corporation, Minneapolis, MN/USAProduktmärkte:Antikörper... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 10,550 | +2,21 % | Innovent Biologics Secures China Commercialization Rights For Vanflyta In Deal With Daiichi Sankyo | BEIJING (dpa-AFX) - Innovent Biologics Inc. (IVBXF, 1801.HK) and Daiichi Sankyo (DSKYF, 4568.T) have entered into an exclusive agreement for the commercialization of Vanflyta (quizartinib) in... ► Artikel lesen | |
| GENSCRIPT BIOTECH | 2,600 | -1,52 % | GenScript Biotech Corporation: GenScript and Tamarind Bio Partner to Connect AI Molecular Design with Rapid Lab Validation | Collaboration combines Tamarind Bio's AI-powered molecular design platform with GenScript's wet-lab capabilities to help researchers move from digital concepts to experimental proofPISCATAWAY... ► Artikel lesen | |
| QUANTUM-SI | 0,814 | 0,00 % | Quantum-Si Incorporated: Quantum-Si Announces the Start of the Proteus Roadshow | Multi-city Roadshow To Drive Awareness of Proteus and Develop Customer Funnel for Commercial Launch Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a proteomics... ► Artikel lesen | |
| AKESO | 11,420 | +2,93 % | Akeso, Inc.: Akeso Advances IO2.0 + ADC2.0 Strategy: First Patient Dosed in Phase II Study of TROP2/Nectin-4 Bispecific ADC (AK146D1) Combined with Ivonescimab in Breast Cancer | HONG KONG, Aug. 10, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase II clinical... ► Artikel lesen | |
| SCILEX | 5,950 | -1,65 % | Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026 | PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and... ► Artikel lesen | |
| ORIGIN AGRITECH | 0,745 | -19,02 % | Origin Agritech Ltd.: Origin Agritech Secures Exclusive Nationwide Rights to Zhongdan 6202, the Flagship Machine-Harvest Corn Hybrid Developed Under China's National 14th Five-Year Plan Breeding Program | ||
| HARMONY BIOSCIENCES | 38,410 | 0,00 % | Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile | WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion... ► Artikel lesen | |
| NIKI BIOSOLUTIONS | 9,000 | +0,11 % | Niki BioSolutions, Inc. - 8-K, Current Report | ||
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen |
PRENETICS GLOBAL LIMITED gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,070 (+0,38 %) liegt der Kurs bei 18,330 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PRENETICS GLOBAL LIMITED finden Sie auf Wallstreet Online.